๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Solid Tumor
Clinical trial register · China

Advanced Solid Tumor Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 63 Shanghai 52 Guangzhou 40 Hangzhou 19 Fuzhou 19
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeOne Medicines11 Suzhou Zelgen Biopharmaceuticals Co.,Ltd4 LaNova Medicines Limited4 MediLink Therapeutics (Suzhou) Co., Ltd.4 Daiichi Sankyo4
Site location
Beijing63 Shanghai52 Guangzhou40 Hangzhou19 Fuzhou19
All 68 locations
Target enrolment
to

Advanced Solid Tumor trials in China

159 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
NCT05048368Esophageal Cancer, Advanced Solid Tumor
Sunshine Lake Pharma Co., Ltd.
Phase 1
32
Chengdu
2026-10-30
Recruiting
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors
NCT07811037Advanced Solid Tumor
Beijing Sungen Biomedical Technology Co., Ltd
Phase 1/2
332
Beijing
2026-08-17
Recruiting
A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors
NCT07669415Advanced Solid Tumor
LaNova Medicines Limited
Phase 2
108
Beijing
2026-07-29
Recruiting
Evaluation of ICP-B208 in Patients With Advanced Solid Tumors
NCT07617493Advanced Solid Tumor
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
539
Beijing
2026-07-03
Not yet open
A Clinical Study of ZL-85FA Tablets
NCT07339748Advanced Solid Tumor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2
51
Hefei
2026-06-30
Recruiting
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
NCT07508761Advanced Solid Tumor
Nanjing Immunophage Biotech Co., Ltd
Phase 1/2
52
Shanghai
2026-06-16
Not yet open
JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC
NCT07582822Advanced Solid Tumor
Biotech Pharmaceutical Co., Ltd.
Phase 1
60
Chongqing, Zhengzhou, Changsha, Nanjing, Xi'an, Shanghai, Taiyuan, Chengdu
2026-05-30
Recruiting
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
NCT07512583Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
178
Beijing, Harbin, Tianjin
2026-05-27
Recruiting
Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors
NCT07752953Advanced Solid Tumor, Cancer, Malignant Solid Tumor
ZSky Biotech Inc
Not applicable
100
Qinhuangdao
2026-05-01
Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT07414836Advanced Solid Tumor
BeOne Medicines
Phase 1
84
Beijing, Chongqing, Fuzhou, Guangzhou, Yichang, Shanghai
2026-04-13
Recruiting
A Study of MG2512 Injection in Participants With Advanced Solid Tumors
NCT07348653Advanced Solid Tumor
Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.
Phase 1
116
Beijing, Chengdu
2026-03-18
Recruiting
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
NCT07380334Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
200
Hangzhou
2026-03-12
Recruiting
A Study of PLB-002 in Advanced Solid Tumors
NCT07304128Advanced Solid Tumor
Primelink BioTherapeitics(ShenZhen) Limited
Phase 1
100
Shanghai
2026-02-06
Recruiting
Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors
NCT07656116Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
27
Langfang
2026-01-29
Recruiting
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
NCT07298772Advanced Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
198
Shanghai
2026-01-07
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Nanjing, Shanghai, Tianjin
2025-12-11
Recruiting
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
NCT07226349Advanced Solid Tumor
BeOne Medicines
Phase 1
105
Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang
2025-12-11
Recruiting
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
NCT07793500NSCLC, Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
36
Beijing
2025-11-27
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07181681Solid Tumors, Advanced Solid Tumor
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
NCT07256782Advanced Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
444
Shanghai
2025-10-24
Recruiting
JMT106 Injection in the Treatment of Advanced Solid Tumors
NCT07275073Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
Shanghai JMT-Bio Inc.
Phase 1
200
Zhejiang
2025-09-25
Recruiting
VSV-02 Compassionate Use in Advanced Solid Tumors
NCT07260591Advanced Solid Tumor, Melanoma, Breast Cancer, Lung Cancer
The First Affiliated Hospital of Xinxiang Medical College
Phase 1
6
Xinxiang
2025-09-22
Recruiting
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Harbin, Shanghai, Hangzhou
2025-09-22
Recruiting
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
NCT06682780Advanced Solid Tumor
LaNova Medicines Limited
Phase 1/2
320
Shanghai
2025-09-17
Not yet open
CVL006 Combination Therapy in Advanced Solid Tumors
NCT07157956Advanced Solid Tumor
Convalife (Shanghai) Co., Ltd.
Phase 1/2
318
Guangzhou
2025-09-10
Not yet open
Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
NCT07142837Advanced Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
153
Beijing
2025-09
Recruiting
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348Advanced Solid Tumor
BioNTech SE
Phase 1/2
375
Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang
2025-08-27
Recruiting
A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors
NCT06973863Advanced Solid Tumor, Solid Tumors, MTAP-deleted Solid Tumors, MTAP Deletion
PharmaEngine
Phase 1
40
2025-08-26
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
BioNTech SE
Phase 1/2
1,438
Hangzhou, Tianjin, Wuhan
2025-08-12
Recruiting
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
NCT07124117Advanced Solid Tumor
OBI Pharma, Inc
Phase 1/2
147
2025-08-04
Recruiting
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
NCT06173219Advanced Solid Tumor
China-Japan Friendship Hospital
Phase 1/2
38
Beijing
2025-08-01
Recruiting
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
NCT07083323Advanced Solid Tumor
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
262
Beijing
2025-07-22
Recruiting
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
NCT06953323Advanced Solid Tumor
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
NCT06992713Advanced Solid Tumor
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Phase 1
36
Nanjing, Beijing, Shanghai
2025-06-18
Active, closed
Study of ZG005 in Patients With Advanced Solid Tumors
NCT06927687Advanced Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
50
Guangzhou
2025-06-13
Active, closed
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
NCT06993116Advanced Solid Tumor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 1
15
Fuzhou, Changsha
2025-06-09
Not yet open
Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation
NCT06970132Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD
Phase 1/2
102
Beijing
2025-06
Recruiting
A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
NCT06936735Advanced Solid Tumor
Hansoh BioMedical R&D Company
Phase 1
502
Shanghai
2025-05-29
Recruiting
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
NCT06938880Advanced Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
60
Guangzhou
2025-05-20
Recruiting
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
NCT06911827Advanced Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
149
Guangzhou
2025-05-09
Recruiting
a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors
NCT06878612Polyphenols, Cancer Vaccine, Advanced Solid Tumor
Xingchen Peng
Phase 1
9
Chengdu
2025-04-21
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
NCT06825494Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
194
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Shenzhen, Nanning, Tangshan
2025-04-08
Recruiting
An Engineered Sirpฮฑ Fused to Anti-Pd-L1 And Tgf-ฮฒ Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
NCT06487624Advanced Solid Tumor, Refractory Hodgkin Lymphoma
FBD Biologics Limited
Phase 1
50
Hangzhou, Xuzhou, Yantai, Zhujiang
2025-04-02
Recruiting
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
NCT06657144Metastatic Solid Tumor, Advanced Solid Tumor
Coherus Oncology, Inc.
Phase 1
154
2025-04-01
Not yet open
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
NCT06873854Advanced Solid Tumor
LaNova Medicines Limited
Phase 2
84
Beijing
2025-03-26
Recruiting
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor
BeOne Medicines
Phase 1
90
Beijing, Nanchang, Shanghai, Taiyuan
2025-03-18
Recruiting
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
NCT06716619Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
32
Guangzhou
2025-02-13
Recruiting
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
NCT06589596Advanced Solid Tumor
BeOne Medicines
Phase 1
525
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-01-10
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors
NCT06772415Advanced Solid Tumor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
163
Beijing, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Tianjin
2025-01-08
Active, closed
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors
Daiichi Sankyo
Phase 2
200
Changsha, Shanghai
2025-01-06
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Zhengzhou, Shanghai, Beijing, Guangzhou
2024-12-27
Recruiting
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
NCT06687070Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor
Ascentage Pharma Group Inc.
Phase 1
90
Guangzhou
2024-12-17
Recruiting
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593Advanced Solid Tumor
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Recruiting
A Study of ES014 in Subjects With Advanced Solid Tumors
NCT06543056Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
15
Beijing
2024-11-25
Recruiting
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
NCT06959615Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
334
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou
2024-11-22
Recruiting
A Study of the ILB-3101 in Patients with Advanced Solid Tumors
NCT06426680Advanced Solid Tumor
Innolake Biopharm
Phase 1
240
Shanghai
2024-10-30
Recruiting
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
NCT06598800Advanced Solid Tumor
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Recruiting
A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors
NCT07135128Advanced Solid Tumor
Xiaorong Sun
Phase 1
20
Jinan
2024-10-14
Active, closed
Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01)
NCT06577194Rectal Cancer, Advanced Solid Tumor
The First Affiliated Hospital with Nanjing Medical University
Phase 2
35
Nanjing
2024-10-09
Recruiting
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
78
Beijing, Changsha, Fuzhou, Guangzhou, Shanghai
2024-09-04
Recruiting
An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment
NCT06497010Advanced Solid Tumor
The Affiliated Hospital Of Guizhou Medical University
Phase EARLY_PHASE1
40
Guiyang
2024-08-29
Recruiting
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
NCT07110883Advanced Solid Tumor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
400
Harbin, Shanghai
2024-08-15
Recruiting
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
NCT06487455Advanced Solid Tumor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
170
Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan
2024-08-06
Recruiting
A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
NCT06512116Advanced Solid Tumor
Shanghai Institute Of Biological Products
Phase 1
196
Beijing
2024-07-23
Recruiting
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
NCT06484816Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
Shenzhen TargetRx Co., Ltd.
Phase 1
90
Hangzhou
2024-07-08
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
Beijing, Guangzhou, Shanghai
2024-07-01
Not yet open
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
NCT06446388Advanced Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 2
360
Beijing
2024-06-30
Recruiting
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
NCT06277219Advanced Solid Tumor
Latticon Antibody Therapeutics, Inc
Phase 1/2
150
Jinan, Hangzhou
2024-06-05
Recruiting
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
NCT06298058Advanced Solid Tumor
Shanghai Institute Of Biological Products
Phase 1
144
Shanghai
2024-05-09
Recruiting
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
NCT06431243Advanced Solid Tumor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2
132
Guanzhou, Chengdu
2024-05-08
Active, closed
A Machine Learning-based Estimated Survival Model
NCT06432283Advanced Solid Tumor
Zhao Siyao
Observational
1,000
Chengdu
2024-05-01
Recruiting
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
NCT06332170Advanced Solid Tumor
Hansoh BioMedical R&D Company
Phase 1
610
Shanghai
2024-04-26
Active, closed
A Study of MHB039A for Advanced Solid Tumor
NCT06345482Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
196
Shanghai
2024-04-16
Recruiting
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
NCT06233942Advanced Solid Tumor
BeOne Medicines
Phase 1
308
Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan
2024-04-12
Active, closed
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT06328673Advanced Solid Tumor
D2M Biotherapeutics Inc.
Phase 1
160
Beijing
2024-04-09
Recruiting
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
NCT06257680Advanced Solid Tumor
Beijing Xunsheng Biomedical Research Co., Ltd.
Phase 1
15
Beijing
2024-04-08
Recruiting
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
NCT06307925Advanced Solid Tumor
HC Biopharma Inc.
Phase 1
122
Guangzhou
2024-03-27
Recruiting
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors
NCT05983523Advanced Solid Tumor, Metastatic Solid Tumor
PharmaEngine
Phase 1
54
2024-03-27
Recruiting
First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.
NCT06240546Advanced Solid Tumor
Luye Pharma Group Ltd.
Phase 1
102
Beijing
2024-03-12
Recruiting
A Study of NBL-028 in Patients With Advanced Solid Tumors
NCT06223256Advanced Solid Tumor
NovaRock Biotherapeutics, Ltd
Phase 1
270
Shijiazhuang
2024-03-08
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Beijing, Changsha, Shanghai
2024-03-05
Recruiting
A Study of HC006 in Subjects With Advanced Solid Tumors
NCT06304571Advanced Solid Tumor
HC Biopharma Inc.
Phase 1
76
Shanghai
2024-02-27
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
Daiichi Sankyo
Phase 2
740
Chengdu, Guangzhou
2024-02-26
Active, closed
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
NCT06244485Advanced Solid Tumor
Daiichi Sankyo
Phase 1
210
Beijing, Guangzhou, Heilongjiang, Hunan, Jilin City, Shandong
2024-02-22
Recruiting
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
NCT06112704Advanced Solid Tumor
Hansoh BioMedical R&D Company
Phase 2
220
Hefei, Fujian, Fuzhou, Guangzhou, Harbin, Anyang, Luoyang, Nanyang
2024-02-06
By invitation
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
NCT06169579Advanced Solid Tumor
Shenzhen NewDEL Biotech, Co., Ltd
Phase 1
96
Xiamen, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Wuโ€™an
2024-02-04
Recruiting
Study SC-101 in Subjects With Advanced Malignancies
NCT06220838Advanced Solid Tumor
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1
100
Beijing, Changsha, Nanjing, Shanghai, Tianjin
2024-02-02
Not yet open
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
NCT06132217Advanced Solid Tumor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Phase 1/2
168
Beijing
2024-01-30
Recruiting
Clinical Trial of BT02 in Patients With Advanced Solid Tumors
NCT06404905Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
60
Beijing
2024-01-24
Recruiting
A Study of NWY001 in Subjects With Advanced Solid Tumors
NCT05979155Advanced Solid Tumor
Chipscreen Biosciences, Ltd.
Phase 1
196
Guangzhou
2024-01-05
Recruiting
MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors
NCT06170294Advanced Solid Tumor
Peking University
Phase 1
20
Beijing
2024-01-01
Recruiting
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
NCT06084286Advanced Solid Tumor
Sichuan University
Phase 1
29
Chengdu
2024-01-01
Recruiting
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
NCT06211647Advanced Solid Tumor
Ruimin Wang
Phase 1
20
Beijing
2024-01
Recruiting
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
NCT06197139Advanced Solid Tumor
Xinlu Wang
Phase 1
20
Guangzhou
2024-01
Recruiting
The Efficacy and Safety of IBI363 in Solid Tumors
NCT06081907Advanced Solid Tumor
Hunan Province Tumor Hospital
Phase 1/2
430
Changsha
2023-12-25
Recruiting
Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors
NCT05916248Advanced Solid Tumor
Ruijin Hospital
Phase EARLY_PHASE1
34
Shanghai
2023-12-20
Recruiting
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
NCT06253130Advanced Solid Tumor
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Study of TRX-920 for Patients With Advanced Solid Tumors
NCT06143774Advanced Solid Tumor
TaiRx, Inc.
Phase 1
30
2023-10-31
Rows per page Showing 1–100 of 159
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/condition/advanced-solid-tumor

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 159 of those studies listing the condition Advanced Solid Tumor.

How many Advanced Solid Tumor trials are recruiting in China?

124 of the 159 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 11 have not yet opened recruitment, 23 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Solid Tumor), 159 studies
PhaseStudiesRecruitingShare
Phase 1847152.8%
Phase 1/2584336.5%
Phase 21046.3%
Phase EARLY_PHASE1553.1%
Not applicable110.6%
Observational100.6%

Most active sponsors

Lead sponsors with the most studies (Advanced Solid Tumor)
Lead sponsorStudiesRecruiting
BeOne Medicines1111
Cancer Institute and Hospital, Chinese Academy of Medical Sciences44
Daiichi Sankyo42
LaNova Medicines Limited42
MediLink Therapeutics (Suzhou) Co., Ltd.43
Suzhou Zelgen Biopharmaceuticals Co.,Ltd42
Hansoh BioMedical R&D Company33
Qilu Pharmaceutical Co., Ltd.32
Xuanzhu Biopharmaceutical Co., Ltd.31
Ascentage Pharma Group Inc.22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.